Fabry Disease Pipeline Insights 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Fabry Disease - Pipeline Insights, 2017" drug pipelines to their offering.

Fabry Disease - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Fabry Disease. This report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Fabry Disease.

This report also assesses the Fabry Disease therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Scope:

  • The report provides competitive pipeline landscape of Fabry Disease
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Fabry Disease pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Fabry Disease and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Fabry Disease Overview
  2. Fabry Disease Pipeline Therapeutics
  3. Fabry Disease Therapeutics under Development by Companies
  4. Fabry Disease Filed and Phase III Products
  5. Fabry Disease Phase II Products
  6. Fabry Disease Phase I and IND Filed Products
  7. Fabry Disease Discovery and Pre-Clinical Stage Products
  8. Drug Candidate Profiles
  9. Fabry Disease - Therapeutics Assessment
  10. Companies Involved in Therapeutics Development for Fabry Disease
  11. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/xnsqw4/fabry_disease

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorders Drugs, Endocrine and Metabolic Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorders Drugs, Endocrine and Metabolic Disorders Drugs